FDA
-
-
-
-
-
-
-
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
-
-
-
-
-
-
-
Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Cardiff Oncology (CRDF) Reports New Preclinical and Clinical Data from KRAS-mutated mCRC Program
-
-
-
-
-
-
-
Cardiff Oncology Announces Departure of Chief Medical Officer
-
-
-
-
-
-
-
Cardiff Oncology (CRDF) Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and PFS
-
-
-
-
-
-
-
Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates
-
-
-
-
-
-
-
Cardiff Oncology Announces the Appointment of Two New Independent Members to its Board of Directors
-
251,531 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All